ARK Space & Defense Innovation ETF vs Hims and Hers Health Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.66, while Hims and Hers Health Inc trades at $29.82 (market cap $7.12B). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | HIMS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $62.76 |
52-Week Low | $25.46 | $14.52 |
Market Cap | — | $7.12B |
Enterprise Value | — | $7.82B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.
The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.
Trailing returns across standard periods
Latest headlines on both assets
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →